Literature DB >> 12814654

Indinavir reduces Cryptosporidium parvum infection in both in vitro and in vivo models.

R Mele1, M A Gomez Morales, F Tosini, E Pozio.   

Abstract

The use of highly active antiretroviral therapy in persons with acquired immunodeficiency syndrome has reduced the prevalence of infection with Cryptosporidium parvum and the length and severity of its clinical course. This effect has in most cases been attributed to the recovery of the host immunity; however, some works suggest that human immunodeficiency virus protease inhibitors, indinavir in particular, which is one of the human immunodeficiency virus protease inhibitors used in highly active antiretroviral therapy, may be capable of controlling Microsporidia and Cryptosporidium infections, which are refractory to other treatments. The objective of the present study was to investigate the effect of human immunodeficiency virus protease inhibitors on C. parvum infections. Since preliminary experiments using ritonavir, saquinavir, and indinavir showed a drastic reduction of C. parvum infection both in vivo (neonatal Balb/c mice) and in vitro (human ileocecal adenocarcinoma tumour cell line) models, indinavir alone was tested in successive experiments. In vitro, the treatment of the sporulated oocysts with different concentrations of indinavir reduced the percentage of human ileocecal adenocarcinoma tumour cell line infected cells in a dose-dependent manner. For established infection, the treatment with 50 microM of indinavir decreased the percentage of infected cells in a time-dependent manner. In vivo, mice treated with indinavir at the same time they were infected with the oocysts showed a 93% reduction in the number of oocysts present in the entire intestinal contents and a 91% reduction in the number of intracellular parasites in the ileum. For established infection, indinavir treatment reduced the number of oocysts in the entire intestinal content by about 50% and the number of intracellular parasites in the ileum by about 70%. These data show that indinavir directly interferes with the cycle of C. parvum, resulting in a marked reduction in oocyst shedding and in the number of intracellular parasites. Protease inhibitors could be considered as good candidates for the treatment of cyptosporidiosis in immunosuppressed persons.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12814654     DOI: 10.1016/s0020-7519(03)00093-6

Source DB:  PubMed          Journal:  Int J Parasitol        ISSN: 0020-7519            Impact factor:   3.981


  13 in total

1.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

Review 2.  The evolution of respiratory Cryptosporidiosis: evidence for transmission by inhalation.

Authors:  Jerlyn K Sponseller; Jeffrey K Griffiths; Saul Tzipori
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

Review 3.  Signal peptide peptidase: a potential therapeutic target for parasitic and viral infections.

Authors:  Christopher Schwake; Michael Hyon; Athar H Chishti
Journal:  Expert Opin Ther Targets       Date:  2022-03-07       Impact factor: 6.797

4.  Cryptosporidium parvum at different developmental stages modulates host cell apoptosis in vitro.

Authors:  Raffaella Mele; Maria Angeles Gomez Morales; Fabio Tosini; Edoardo Pozio
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

5.  Cryptosporidium parvum-specific CD4 Th1 cells from sensitized donors responding to both fractionated and recombinant antigenic proteins.

Authors:  Maria Angeles Gomez Morales; Raffaella Mele; Alessandra Ludovisi; Fabrizio Bruschi; Fabio Tosini; Rachele Riganò; Edoardo Pozio
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

Review 6.  Giardia and Cryptosporidium and public health: the epidemiological scenario from the Italian perspective.

Authors:  Annunziata Giangaspero; Federica Berrilli; Olga Brandonisio
Journal:  Parasitol Res       Date:  2007-06-26       Impact factor: 2.289

7.  Treatment of Cryptosporidium: What We Know, Gaps, and the Way Forward.

Authors:  Hayley Sparks; Gayatri Nair; Alejandro Castellanos-Gonzalez; A Clinton White
Journal:  Curr Trop Med Rep       Date:  2015-08-01

8.  HIV Protease Inhibitors: Effect on the Opportunistic Protozoan Parasites.

Authors:  Yenisey Alfonso; Lianet Monzote
Journal:  Open Med Chem J       Date:  2011-03-09

9.  The impact of asymptomatic helminth co-infection in patients with newly diagnosed tuberculosis in north-west Ethiopia.

Authors:  Ebba Abate; Meseret Belayneh; Aschalew Gelaw; Jonna Idh; Assefa Getachew; Shitaye Alemu; Ermias Diro; Nigussu Fikre; Sven Britton; Daniel Elias; Abraham Aseffa; Olle Stendahl; Thomas Schön
Journal:  PLoS One       Date:  2012-08-29       Impact factor: 3.240

10.  Nelfinavir is effective in inhibiting the multiplication and aspartic peptidase activity of Leishmania species, including strains obtained from HIV-positive patients.

Authors:  Lívia O Santos; Bianca S Vitório; Marta H Branquinha; Conceição M Pedroso e Silva; André L S Santos; Claudia M d'Avila-Levy
Journal:  J Antimicrob Chemother       Date:  2012-10-28       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.